47
2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. Fortunately, despite all that, great science and medicine continues to advance.
This month we held our 2023 Annual General Meeting for our fund’s investors and our Atlas Venture Retreat with industry executives. As in the past, we’ve kicked off each of these meetings with our Year In Review.
This year we start with a deep dive into the biomedical innovation across our industry – “putting the Big back into Big Pharma” with obesity and Alzheimer’s, and the state of…